- Home
- QSG vs VSTM Comparison
QSG vs VSTM Comparison
Compare QSG & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSG
- VSTM
- Stock Information
- Founded
- QSG 2019
- VSTM 2010
- Country
- QSG China
- VSTM United States
- Employees
- QSG N/A
- VSTM N/A
- Industry
- QSG Other Consumer Services
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- QSG Real Estate
- VSTM Health Care
- Exchange
- QSG Nasdaq
- VSTM Nasdaq
- Market Cap
- QSG 360.9M
- VSTM 425.9M
- IPO Year
- QSG 2023
- VSTM 2012
- Fundamental
- Price
- QSG $11.97
- VSTM $4.93
- Analyst Decision
- QSG Strong Buy
- VSTM Strong Buy
- Analyst Count
- QSG 1
- VSTM 8
- Target Price
- QSG $9.52
- VSTM $12.71
- AVG Volume (30 Days)
- QSG 1.9M
- VSTM 2.6M
- Earning Date
- QSG 06-06-2025
- VSTM 08-07-2025
- Dividend Yield
- QSG 1.72%
- VSTM N/A
- EPS Growth
- QSG 92.28
- VSTM N/A
- EPS
- QSG 1.12
- VSTM N/A
- Revenue
- QSG $428,283,608.00
- VSTM $10,000,000.00
- Revenue This Year
- QSG N/A
- VSTM $129.06
- Revenue Next Year
- QSG N/A
- VSTM $306.32
- P/E Ratio
- QSG $10.43
- VSTM N/A
- Revenue Growth
- QSG N/A
- VSTM N/A
- 52 Week Low
- QSG $1.50
- VSTM $2.10
- 52 Week High
- QSG $15.64
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- QSG 74.32
- VSTM 30.80
- Support Level
- QSG $5.26
- VSTM $5.73
- Resistance Level
- QSG $15.64
- VSTM $6.62
- Average True Range (ATR)
- QSG 1.57
- VSTM 0.46
- MACD
- QSG 0.61
- VSTM -0.17
- Stochastic Oscillator
- QSG 75.53
- VSTM 0.84
About QSG QuantaSing Group Limited
QuantaSing Group Ltd is a lifestyle solution provider. The company offers engaging, affordable, and accessible online and offline services, as well as consumer products in selected areas that address adult learners. The group has expanded into the pop toys sector and continues to strategically diversify its portfolio by capturing opportunities in consumer sectors while maintaining financial discipline.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.